-
601
-
602
-
603
An Amorphous (Al<sub>0.12</sub>Ga<sub>0.88</sub>)<sub>2</sub>O<sub>3</sub> Deep Ultraviolet Photodetector
Published 2020-01-01Get full text
Article -
604
-
605
Alexey Remizov and Boris Zaitsev: 1926 Anniversary Preparation
Published 2021-12-01Get full text
Article -
606
-
607
-
608
Unveiling lives: A glimpse into the daily routines of individuals affected by leprosy in Malaysia using the walk-and-talk technique
Published 2025-12-01“…Visual, auditory, and field data were transcribed and thematically analysed using NVivo 12, revealing key themes, including resilience and perseverance, employment and economic sustenance, stigma, family support, and community engagement. …”
Get full text
Article -
609
-
610
-
611
Designing electronic equipment on the basis of standard mechanical structures using internet resources
Published 2016-12-01Get full text
Article -
612
Formación inicial de los maestros y las maestras de primaria en derechos humanos en España
Published 2022-01-01Get full text
Article -
613
AS PRÁTICAS DE LINGUAGEM NA AULA DE LÍNGUA PORTUGUESA NO ENSINO FUNDAMENTAL: SOBRE O QUE ESTAMOS FALANDO?
Published 2024-12-01Get full text
Article -
614
Yakov Isidorovich Perelman: um pioneiro da divulgação científica esquecido (Parte I: vida e obra)
Published 2025-02-01Get full text
Article -
615
-
616
The effectiveness of catheter ablation in paroxysmal atrial fibrillation in patients with obstructive sleep apnea with/without use of continuous positive airway pressure: results o...
Published 2020-04-01“…The follow-up period was 12 months and included visits after 3, 6 and 12 months. …”
Get full text
Article -
617
-
618
-
619
HRS-4642 combined with nimotuzumab in the treatment of recurrent or metastatic pancreatic ductal adenocarcinoma: study protocol of a single-arm, prospective phase Ib/II trial
Published 2025-07-01“…Combining KRAS and EGFR inhibitors has shown clinical efficacy in select solid tumors.ObjectivesTo assess the safety and efficacy of HRS-4642 (KRAS G12D inhibitor) plus nimotuzumab (EGFR inhibitor) in patients harboring the KRAS G12D mutation, recurrent/metastatic PDAC refractory to standard systemic therapy.DesignThis is an open-label, single-center, exploratory clinical trial.MethodsThis study will enroll patients with histologically or cytologically confirmed recurrent or metastatic PDAC harboring the KRAS G12D mutation, who have documented disease progression or intolerance to first-line systemic therapy. …”
Get full text
Article -
620